| 5.56 0 (-1.44%) | 09-24 12:38 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.72 | 1-year : | 9.01 |
| Resists | First : | 6.61 | Second : | 7.71 |
| Pivot price | 5.46  |
|||
| Supports | First : | 4.82 | Second : | 4.01 |
| MAs | MA(5) : | 5.48 |
MA(20) : | 5.7 |
| MA(100) : | 5.74 |
MA(250) : | 7.31 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 42.5 |
D(3) : | 38.6 |
| RSI | RSI(14): 45.4 |
|||
| 52-week | High : | 13.68 | Low : | 3.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALGS ] has closed below upper band by 48.8%. Bollinger Bands are 28% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.94 - 5.97 | 5.97 - 5.99 |
| Low: | 5.38 - 5.42 | 5.42 - 5.44 |
| Close: | 5.51 - 5.56 | 5.56 - 5.6 |
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
Mon, 21 Sep 2026
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
Thu, 30 Jul 2026
Aligos Therapeutics to report results before markets open Aug. 6 - Stock Titan
Thu, 30 Jul 2026
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 - Yahoo Finance
Wed, 08 Jul 2026
H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy - Investing.com
Wed, 24 Jun 2026
Lawrence M. Blatt Discloses Investment at Aligos Therapeutics with 5.6% Stake - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.7e+006 (%) |
| Held by Institutions | 10.6 (%) |
| Shares Short | 521 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.792e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -241.1 % |
| Operating Margin | -6.9 % |
| Return on Assets (ttm) | -49.2 % |
| Return on Equity (ttm) | -113.6 % |
| Qtrly Rev. Growth | 2 % |
| Gross Profit (p.s.) | 334.12 |
| Sales Per Share | 1.35279e+007 |
| EBITDA (p.s.) | -2.44034e+007 |
| Qtrly Earnings Growth | -7.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -94 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 2.49 |
| Dividend | 0 |
| Forward Dividend | 568060 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|